Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-08-2019 | Hepatocellular Carcinoma | Original Article – Cancer Research

A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion

Authors: Meile Mo, Shun Liu, Xiaoyun Ma, Chao Tan, Liangjia Wei, Yonghong Sheng, Yanye Song, Xiaoyun Zeng, Dongping Huang, Xiaoqiang Qiu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2019

Abstract

Background

Increasing evidence has shown that long non-coding RNAs (lncRNAs) are important in hepatocellular carcinoma (HCC) development and progression. In this study, we aim to evaluate the expression of lncRNA FAM99B and its biological function in HCC.

Methods

The expression level of FAM99B in HCC was assessed based on data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), verified using quantitative real-time polymerase chain reaction (qRT-PCR). HCCLM3 was transfected with lentivirus containing full-length FAM99B to obtain stable overexpressing cell line. Cell Counting Kit 8, clone formation, and transwell assays were used to investigate the effects of FAM99B in HCC progression. In addition, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and PANTHER pathway analyses were conducted to investigate the underlying molecular mechanisms.

Results

FAM99B was found to be downregulated in HCC tissues compared with adjacent normal tissues based on TCGA, GEO, and qRT-PCR data. Our results revealed that downregulated FAM99B was significantly associated with vascular invasion, advanced histologic grade, and T stage. Kaplan–Meier analysis using TCGA data indicated that decreased FAM99B levels were significantly associated with poor overall survival in patients with HCC. Moreover, overexpression of FAM99B significantly inhibited cell proliferation, migration, and invasion in vitro. Pathway analyses showed that the co-expressed genes of FAM99B mainly participated in the pathways “Metabolic pathways” and “Blood coagulation”.

Conclusion

Our results suggest that FAM99B may serve as a tumor suppressor in HCC and may provide a promising therapy target for patients with HCC.

Available only for authorised users

Adler P, Kolde R, Kull M, Tkachenko A, Peterson H, Reimand J, Vilo J (2009) Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods. Genome Biol 10:R139. https://doi.org/10.1186/gb-2009-10-12-r139 CrossRefPubMedPubMedCentral

Atanasovska B et al (2017) A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis. Hepatology 66:794–808. https://doi.org/10.1002/hep.29034 CrossRefPubMed

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed

Boccaccio C, Medico E (2006) Cancer and blood coagulation. Cell Mol Life Sci 63:1024–1027. https://doi.org/10.1007/s00018-005-5570-9 CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Cerami E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 CrossRefPubMed

Chang J et al (2004) miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1:106–113CrossRefPubMed

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20. https://doi.org/10.1016/j.cmet.2007.10.002 CrossRefPubMed

DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45:139–145. https://doi.org/10.1016/j.cct.2015.09.002 CrossRefPubMedPubMedCentral

Fagerberg L et al (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom 13:397–406. https://doi.org/10.1074/mcp.M113.035600 CrossRef

Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2 CrossRefPubMed

Gao J et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:l1. https://doi.org/10.1126/scisignal.2004088 CrossRef

Ge Z et al (2017) Long noncoding RNA SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma. Cancer Sci 108:653–662. https://doi.org/10.1111/cas.13200 CrossRefPubMedPubMedCentral

Gutschner T, Diederichs S (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9:703–719. https://doi.org/10.4161/rna.20481 CrossRefPubMedPubMedCentral

He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J (2014) Long noncoding RNAs: novel insights into hepatocelluar carcinoma. Cancer Lett 344:20–27. https://doi.org/10.1016/j.canlet.2013.10.021 CrossRefPubMed

He J et al (2019) A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. Cancer Lett 450:98–109. https://doi.org/10.1016/j.canlet.2019.02.033 CrossRefPubMed

Huang S, He X (2011) The role of microRNAs in liver cancer progression. Br J Cancer 104:235–240. https://doi.org/10.1038/sj.bjc.6606010 CrossRefPubMed

Kessler SM et al (2014) Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma. Int J Mol Sci 15:5762–5773. https://doi.org/10.3390/ijms15045762 CrossRefPubMedPubMedCentral

Lanzafame M, Bianco G, Terracciano LM, Ng CKY, Piscuoglio S (2018) The role of long non-coding RNAs in hepatocarcinogenesis. Int J Mol Sci. https://doi.org/10.3390/ijms19030682 CrossRefPubMedPubMedCentral

Lee GL, Dobi A, Srivastava S (2011) Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol 8:123–124. https://doi.org/10.1038/nrurol.2011.10 CrossRefPubMed

Li J et al (2015) TANRIC: an interactive open platform to explore the function of lncRNAs in cancer. Cancer Res 75:3728–3737. https://doi.org/10.1158/0008-5472.can-15-0273 CrossRefPubMedPubMedCentral

Liu J, Lu C, Xiao M, Jiang F, Qu L, Ni R (2017) Long non-coding RNA SNHG20 predicts a poor prognosis for HCC and promotes cell invasion by regulating the epithelial-to-mesenchymal transition. Biomed Pharmacother 89:857–863. https://doi.org/10.1016/j.biopha.2017.01.011 CrossRefPubMed

Ni W et al (2017) A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol 10:91. https://doi.org/10.1186/s13045-017-0449-4 CrossRefPubMedPubMedCentral

Sciacovelli M, Frezza C (2017) Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J 284:3132–3144. https://doi.org/10.1111/febs.14090 CrossRefPubMedPubMedCentral

Sun QM et al (2018) Long non-coding RNA00607 as a tumor suppressor by modulating NF-kappaB p65/p53 signaling axis in hepatocellular carcinoma. Carcinogenesis. https://doi.org/10.1093/carcin/bgy113 CrossRefPubMedPubMedCentral

Vander Heiden MG et al (2011) Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 76:325–334. https://doi.org/10.1101/sqb.2012.76.010900 CrossRefPubMed

Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH (2014) Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol 38:706–714. https://doi.org/10.1016/j.clinre.2014.06.008 CrossRefPubMed

Wang HP, Rogler CE (1988) Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet Cell Genet 48:72–78. https://doi.org/10.1159/000132593 CrossRefPubMed

Wang H et al (2018) Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-kappaB pathway in hepatocellular carcinoma. Theranostics 8:2814–2829. https://doi.org/10.7150/thno.23012 CrossRefPubMedPubMedCentral

Xie C et al (2011) KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res 39:W316–W322. https://doi.org/10.1093/nar/gkr483 CrossRefPubMedPubMedCentral

Yao J et al (2017) Profiling, clinicopathological correlation and functional validation of specific long non-coding RNAs for hepatocellular carcinoma. Mol Cancer 16:164. https://doi.org/10.1186/s12943-017-0733-5 CrossRefPubMedPubMedCentral

Yuan SX et al (2012) Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology 56:2231–2241. https://doi.org/10.1002/hep.25895 CrossRefPubMed

Zhou XD (2002) Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobil Pancreat Dis Int 1:35–41

Title: A liver-specific lncRNA, FAM99B, suppresses hepatocellular carcinoma progression through inhibition of cell proliferation, migration, and invasion
Authors: Meile Mo
Shun Liu
Xiaoyun Ma
Chao Tan
Liangjia Wei
Yonghong Sheng
Yanye Song
Xiaoyun Zeng
Dongping Huang
Xiaoqiang Qiu
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Journal of Cancer Research and Clinical Oncology / Issue 8/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02954-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2019

Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis

Correction to: Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series

Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer

Kaplan–Meier analysis of salivary gland tumors: prognosis and long-term survival

FOXP3 immunoregulatory gene variants are independent predictors of human papillomavirus infection and cervical cancer precursor lesions

Ginger extract has anti-leukemia and anti-drug resistant effects on malignant cells

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage